Fostamatinib Disodium FDA approval date

The FDA approved Fostamatinib Disodium (R788) on 17 Apr 2018.

FDA approval date
17 Apr 2018

Drug identity checked against registry records

Also recorded as Fostamatinib; R788; R935788

Included trials

TrialSponsorPhaseStatusPrimary completion
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)NCT02077192Rigel PharmaceuticalsPhase 3Completed2020-06-02Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2018-04-17DayFostamatinib DisodiumFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA209299", "applicant_as_listed_by_fda": "RIGEL PHARMS", "brand_names": ["TAVALISSE"], "active_ingredients": ["FOSTAMATINIB DISODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180417", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026